Trusted Resources: Education
Scientific literature and patient education texts
Expert Recommendations and Clinical Considerations in the Use of Onasemnogene Abeparvovec Gene Therapy for Spinal Muscular Atrophy
source: Muscle and Nerves
authors: Elizabeth A. Kichula, Crystal M. Proud, Michelle A. Farrar, Jennifer M. Kwon, Kayoko Saito, Isabelle Desguerre, Hugh J. McMillansummary/abstract:
Spinal muscular atrophy (SMA) is an autosomal recessive, neurodegenerative disease caused by biallelic mutations in the survival motor neuron 1 (SMN1) gene. SMA is characterized by motor neuron degeneration, resulting in progressive muscle atrophy and weakness. Before the emergence of disease-modifying therapies, children with the most severe form of SMA would never achieve the ability to sit independently. Only 8% survived beyond 20 months of age without permanent ventilator support. One such therapy, onasemnogene abeparvovec, an adeno-associated virus–based gene replacement therapy, delivers functional human SMN through a one-time intravenous infusion.
In addition to substantially improving survival, onasemnogene abeparvovec was found to increase motor milestone attainment and reduce the need for respiratory or nutritional support in many patients. This expert opinion provides recommendations and practical considerations on the patient-centered decisions to use onasemnogene abeparvovec. Recommendations include the need for patient-centered multidisciplinary care and patient selection to identify those with underlying medical conditions or active infections to reduce risks.
organization: Children's Hospital of Philadelphia, USA; Children's Hospital of the King's Daughters, USA; Sydney Children's Hospital Network, Australia; School of Medicine and Public Health, USA; Institute of Medical Genetics, Japan; Necker-Enfants Malades Hospital, France; Children's Hospital of Eastern Ontario, Canada
Pediatric Spinal Muscular AtrophyWhat is spinal muscular atrophy (SMA)?Sp...
A Caregiver’s Guide to ZolgensmaIndication ZOLGENSMA® (onasemnogene abe...
Baby First at UNC to Receive Gene Therapy for SMA, Thanks to Early Check Newborn ScreeningIt was a pregnancy that went relatively ...
Sofia’s Story – Johns Hopkin’sOn the morning of Friday, Aug. 23, 2019,...
New Treatment Can Help Fresno Infant With Rare Genetic DisorderA Fresno family is holding onto hope aft...
Will Parental Vaccine Hesitancy Retard the Embrace of Life-Saving Newborn Genetic Screening and Emerging Gene Therap...In these days of the never-ending pandem...
Spinal Muscular Atrophy 2019: SMA Pathophysiology, Diagnosis and Clinical Presentationshttps://www.youtube.com/watch?v=cUuWue8M...